eltrombopag olamine
Generic: ELTROMBOPAG OLAMINE·Brand: ELTROMBOPAG OLAMINE, PROMACTA, PROMACTA KIT
eltrombopag olamine: developed by 1 company · 2 FDA decisions.
eltrombopag olamine evidence translation
What we can confirm
2 FDA records
What it means
Source-backed records connect eltrombopag olamine to NVS; that link alone does not prove the drug works.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
How could eltrombopag olamine → NVS affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
Development Pipeline (2)
| Company | Phase |
|---|---|
| Novartis AG (NVS) | Approved |
| Novartis AG (NVS) | Approved |
FDA Decisions2 records
Frequently asked questions
Who is developing eltrombopag olamine?
eltrombopag olamine is being developed by Novartis AG.
What is eltrombopag olamine's latest FDA decision?
The most recent tracked FDA decision for eltrombopag olamine is Approval, dated August 24, 2015.